Hyderabad: Scientists on Tuesday said that the results of phase 2 trial of a
(TB) vaccine— M72/ASO1e candidate vaccine — being developed by GSK pharmaceuticals, have demonstrated a sustained level of protection against active
Overall efficacy was found to be 50% over a span of three years of vaccination. The trial for the vaccine was conducted in TB endemic regions of Kenya, South Africa and Zambia and involved 3,573 participants aged between 18 to 50 years. While these are only initial results and the vaccine will have to pass through many more stages and trials before it can be licensed, the results are important as there is no vaccine for active TB in the world at present. The final results of the phase 2 study of the vaccine were announced at the 50th Union World Conference on lung health here on Tuesday. “In the final analysis, 13 participants in the vaccine group developed active pulmonary TB compared to 26 participants in the placebo group. Among participants who received the vaccine, an increased immune response was sustained for three years. The results show that M72/AS01 could be an important tool in the fight against pulmonary TB, but additional trials need to be conducted to confirm these findings in other populations,” said International Union Against Tuberculosis and Lung Disease (The Union). As per the results, the vaccine was found to reduce the incidence of pulmonary TB in HIV negative adults with latent TB infection.